Leukemia growth is inhibited by benzoxime without causing any harmful effect in rats bearing RBL‑1 xenotransplants

Li,Yingchun; Wang,Huihan; Zhang,Rong; Zhang,Guojun; Yang,Ying; Liu,Zhuogang

doi:10.3892/ol.2018.9783

Leukemia growth is inhibited by benzoxime without causing any harmful effect in rats bearing RBL‑1 xenotransplants

Authors:
- Yingchun Li
- Huihan Wang
- Rong Zhang
- Guojun Zhang
- Ying Yang
- Zhuogang Liu
View Affiliations

Affiliations: Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, Liaoning 110021, P.R. China
Published online on: November 30, 2018 https://doi.org/10.3892/ol.2018.9783
Pages: 1934-1938

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effect of benzoxime on leukemia RBL‑1 cell proliferation and a leukemic Sprague‑Dawley rat model. Proliferation of RBL‑1 cells was determined using an MTT assay. Sprague‑Dawley rats were assigned randomly into three groups of 10 animals each, where the positive control group was administered an intravenous injection of normal saline, the negative control group was administered 1x106 RBL‑1 cells and the treatment group was administered with 1x106 RBL‑1 cells and then benzoxime (50 mg/kg/day) for 1 week. Increased dosage of benzoxime reduced RBL‑1 cell viability from 92 at 2 µM to 21% at 12 µM after 24 h. Benzoxime treatment prevented the loss of body weight in the rats with leukemia. Compared with the negative control rats, the body weight was determined to be significantly reduced (P<0.05) in the positive control rats. The weight of the spleen and liver was determined to be significantly increased (P<0.02) in the positive control rats and the benzoxime‑treated rats compared with that in the negative control group on day 35 of RBL‑1 cell implantation. Analysis of leukocytes in rats on day 35 demonstrated a significant reduction (P<0.05) in the cluster of differentiation (CD)11b and CD45 level in the positive control group compared with that in the negative control group. The level of CD11b and CD45 was determined to be similar in the rats in the benzoxime treatment and negative control groups. Analysis of the level of serum glutamic pyruvic transaminase, serum glutamic oxaloacetic transaminase and blood urea nitrogen indicated that all three components exhibited no significant changes in the rats following treatment with benzoxime compared with the component levels in the negative control group. The levels of these three components were in the normal range in rats treated with benzoxime on day 35 of cell implantation. These data demonstrated that the liver and kidneys are not influenced by benzoxime in rats with leukemia. In summary, the present study demonstrated that benzoxime efficiently prevents leukemia growth without inducing any harmful effects in rat models through targeting CD11b and CD45 level; thus, benzoxime should be evaluated further regarding its use in the treatment of leukemia.

View Figures

View References

1	Liu YQ, Zhao FJ, Chen WQ, et al: An analysis of incidence and mortality of leukemia in China, 2009. China Cancer. 7:528–534. 2013.
2	ESPíRITO Santo AE, Chacim S, Ferreira I, Leite L, Moreira C, Pereira D, Dantas Brito MD, Nunes M, Domingues N, Oliveira I, et al: Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia. Oncol Lett. 12:262–268. 2016. View Article : Google Scholar : PubMed/NCBI
3	Li WX, Li YK and Lin HT: Correlation between survivin polymorphism and acute leukemia of children. Expt Ther Med. 15:2941–2945. 2018.
4	Jiang KL, Ma PP, Yang XQ, Zhong L, Wang H, Zhu XY and Liu BZ: Neutrophil elastase and its therapeutic effect on leukemia cells. Mol Med Rep. 12:4165–4172. 2015. View Article : Google Scholar : PubMed/NCBI
5	Yildirim R, Gundogdu M, Ozbıcer A, Kiki I, Erdem F and Dogan H: Acute promyelocytic leukemia, centre, experience, Turkey. Transfus Apher Sci. 48:45–49. 2013. View Article : Google Scholar : PubMed/NCBI
6	Guo J, Chang CK and Li X: Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 20:1020–1024. 2012.(In Chinese). PubMed/NCBI
7	Kinoshita K and Funauchi M: Therapeutic effect of retinoic acid in lupus nephritis. Nihon Rinsho Meneki Gakkai Kaishi. 35:1–7. 2012.(In Japanese). View Article : Google Scholar : PubMed/NCBI
8	Flatt T, Neville K, Lewing K and Dalal J: Successful treatment of fanconi anemia and T-cell acute lymphoblastic leukemia. Case Report Hematol. 2012:3963952012.
9	Estey EH: Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 87:89–99. 2012. View Article : Google Scholar : PubMed/NCBI
10	Wang TT and Chen BA: Leukemia stem/progenitor cells and target therapy for leukemia-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18:1654–1658. 2010.(In Chinese). PubMed/NCBI
11	Zhai YK, Pan YL, Niu YB, Li CR, Wu XL, Fan WT, Lu TL, Mei QB and Xian CJ: The importance of the prenyl group in the activities of osthole in enhancing bone formation and inhibiting bone resorption in vitro. Int J Endocrinol. 2014:9219542014. View Article : Google Scholar : PubMed/NCBI
12	Yogesh HS, Chandrashekhar VM, Katti HR, Ganapaty S, Raghavendra HL, Gowda GK and Goplakhrishna B: Anti-osteoporotic activity of aqueous-methanol extract of Berberis aristata in ovariectomized rats. J Ethnopharmacol. 134:334–338. 2011. View Article : Google Scholar : PubMed/NCBI
13	Lee WS, Lee EG, Sung MS and Yoo WH: Kaempferol inhibits IL-1β-stimulated, RANKL-mediated osteoclastogenesis via downregulation of MAPKs, c-Fos, and NFATc1. Inflammation. 37:1221–1230. 2014. View Article : Google Scholar : PubMed/NCBI
14	Tyagi AM, Srivastava K, Singh AK, Kumar A, Changkija B, Pandey R, Lahiri S, Nagar GK, Yadav DK, Maurya R, et al: Formononetin reverses established osteopenia in adult ovariectomized rats. Menopause. 19:856–863. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Sener M, Kocak A and Yologlu S: Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem. 294:137–144. 2007. View Article : Google Scholar : PubMed/NCBI
16	Gatson JW, Liu MM, Abdelfattah K, Wigginton JG, Smith S, Wolf S and Minei JP: Resveratrol decreases inflammation in the brain of mice with mild traumatic brain injury. J Trauma Acute Care Surg. 74:470–475. 2013. View Article : Google Scholar : PubMed/NCBI
17	Lin CJ, Chen TH, Yang LY and Shih CM: Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death. Cell Death Dis. 5:e11472014. View Article : Google Scholar : PubMed/NCBI
18	Lin C, Yang JS, Tsai SC, Lin CF and Lee MR: In vivo evaluation of the synthesized novel 2-benzyloxybenzaldehyde analog CCY-1a-E2 for the treatment of leukemia in the BALB/c mouse WEHI-3 allograft model. Oncol Lett. 5:777–782. 2013. View Article : Google Scholar : PubMed/NCBI
19	Alayev A, Sun Y, Snyder RB, Berger SM, Yu JJ and Holz MK: Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells. Cell Cycle. 13:371–382. 2014. View Article : Google Scholar : PubMed/NCBI
20	Li H, Zhai Z, Liu G, Tang T, Lin Z, Zheng M, Qin A and Dai K: Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways. Biochem Biophys Res Commun. 430:951–956. 2013. View Article : Google Scholar : PubMed/NCBI
21	Mackraj I, Govender T and Gathiram P: Sanguinarine. Cardiovasc Ther. 26:75–83. 2008.PubMed/NCBI
22	Chung JG, Yang JS, Huang LJ, Lee FY, Teng CM, Tsai SC, Lin KL, Wang SF and Kuo SC: Proteomic approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Proteomics. 7:3305–3317. 2007. View Article : Google Scholar : PubMed/NCBI
23	Lu CC, Yang JS, Chiang JH, Hour MJ, Lin KL, Lin JJ, Huang WW, Tsuzuki M, Lee TH and Chung JG: Novel quinazolinone MJ-29 triggers endoplasmic reticulum stress and intrinsic apoptosis in murine leukemia WEHI-3 cells and inhibits leukemic mice. PLoS One. 7:e368312012. View Article : Google Scholar : PubMed/NCBI
24	Chiang JH, Yang JS, Ma CY, Yang MD, Huang HY, Hsia TC, Kuo HM, Wu PP, Lee TH and Chung JG: Danthron, an anthraquinone derivative, induces DNA damage and caspase cascades-mediated apoptosis in SNU-1 human gastric cancer cells through mitochondrial permeability transition pores and Bax-triggered pathways. Chem Res Toxicol. 24:20–29. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hsu SC, Ou CC, Li JW, Chuang TC, Kuo HP, Liu JY, Chen CS, Lin SC, Su CH and Kao MC: Ganoderma tsugae extracts inhibit colorectal cancer cell growth via G(2)/M cell cycle arrest. J Ethnopharmacol. 120:394–401. 2008. View Article : Google Scholar : PubMed/NCBI
26	Yang JS, Wu CC, Kuo CL, Lan YH, Yeh CC, Yu CC, Lien JC, Hsu YM, Kuo WW, Wood WG, et al: Solanum lyratum extracts induce extrinsic and intrinsic pathways of apoptosis in WEHI-3 murine leukemia cells and inhibit allograft tumor. Evid Based Complement Alternat Med. 2012:2549602012. View Article : Google Scholar : PubMed/NCBI
27	Li J and Sartorelli AC: Synergistic induction of the differentiation of WEHI-3B D+ myelomonocytic leukemia cells by retinoic acid and granulocyte colony-stimulating factor. Leuk Res. 16:571–576. 1992. View Article : Google Scholar : PubMed/NCBI
28	Barr RD and Harnish D: Induction of differentiation of HL-60 and WEHI-3B D+ leukemia cells by lithium chloride. Leuk Res. 17:1017–1018. 1993. View Article : Google Scholar : PubMed/NCBI